Methods From 2001 to 2016, incidence rates of cervical cancer were estimated from United States Cancer Statistics. SEER*Stat and Joinpoint regression were used to calculate the incidence rate (per 100,000) and average annual percent change (AAPC), adjusted for hysterectomy and pregnancy prevalence data from the Behavioral Risk Factor Surveillance System.

Results Adenosquamous cell carcinoma accounted for 6,599 of 200,000 (3.3%) cases of cervical cancer from 2001–2016; of which 4,165 were White (63.1%), 830 were Black (12.6%), 1,155 were Hispanic (17.5%), 345 were Asian (5.2%) and 104 were unidentified (1.6%). There was a 3.9% decrease in incidence per year; from 0.47/100,000 in 2001 to 0.24/100,000 in 2016 after adjusting for age and race (p<0.001). The incidence of ASC is nearly 1.5-fold greater for Hispanics at 0.38 per 100,000 compared to Whites (0.25) and Blacks (0.27). Additionally, the Hispanics had a bimodal age distribution at diagnosis, with peaks at 40–44yo and 65–69yo (0.76 and 0.69) compared to Whites with a single peak diagnosis at 40–44yo (0.56/100,000).

Conclusion Hispanics have a 50% higher incidence of adenosquamous cell cervical carcinoma compared to others. Their incidence peaks in the early 40’s and late 60’s year olds. The difference in incidence and age distribution of this cancer warrant further investigation.

Abstract 142 Figure 1

IGCS20_1120

DEVELOPMENT AND CLINICAL APPLICATION OF A TOOL TO IDENTIFY FRAILTY IN ELDERLY PATIENTS WITH GYNECOLOGICAL CANCERS

A Ferrero*, M Villa, D Attiassese, M Coppo, M Borghese, E Badellino, L Fuso, N Biglia. Academic Department Gynaecology and Obstetrics – Mauriziano Hospital, Italy

10.1136/ijgc-2020-IGCS.123

Objectives Aim of this prospective study is the development and clinical application of a tool to identify frailty in patients > 70 years old affected by either ovarian or endometrial cancer. After identifying a cut off to establish frailty, differences in terms of surgical complications and chemotherapy toxicities were verified.

Methods The test consists of 20 items combining comorbidities and functional aspects. At the onset or at the first recurrence 52 patients were evaluated before treatment’s administration.

Results Considering ‘completion of treatment’ as parameter to discriminate frail patients, a cut off > 4 resulted the best in